Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
Exciting news for the world about vaccines!
These efficacy figures are soon after vaccination. Everyone expects this to wane by next winter and completely unknown how much (if any) protection will remain by then.
Any protection will be used to allow the economy to open up while keeping cases below what the NHS can manage rather than pushing down infections.
I completely expect further waves next winter and probably for years to come. Only question is how bad they will be. If vaccination means that mutations not covered by the vaccine thrive it may be no better than this year. There are already large numbers of mutated strains circulating and will be many more to come. It is only after vaccine roll out that we will see new strains taking hold.
Claims that SNG have 'missed the boat' are absurd.
Sorry if already said..
I am sure Synairgen are aware of this possibility. The nebuliser is used under zoom supervision, so I am sure they check the name on the vial and watch as it is opened and used. They don't design good controlled studies and leave loopholes like this.
Publicity for AIM awards starts next week, with winners announced the following week.
This may raise our profile!
http://www.aim-awards.co.uk/media-room/
Hello BumbleB.
Yes, I am down to my last 315 AFC shares.
Holding was very much more than that in the past, so I am 'out'.
I am watching though. I do see Alkamem as a potential game changer and the solid fuel cell may be if it is at a competitive price.
I may be back in the future. I would be disappointed to find this actually involves another 5 years of testing to increase durability though.
I also just had enough of jam tomorrow as well as all the secrecy. Just felt there was contempt for shareholders who had entrusted the BOD with a great deal of their hard earned. I am sure I don't need to mention a particular name!!
Very good tweet and interview. Suggesting the Pfizer trial should be allowed to run and follow the protocol, ie do science properly. This is what Synairgen are doing. I suspect vaccine timelines will be much longer when the penny drops that this is needed for approvals. Or, if approvals are rushed through a lot of trust will be lost/people with sense will not take it.
Someone on BBC news just talking about the oxford vaccine. Pointing out that mRNA vaccines have never been used before while the Oxford one is a more tested approach. Saying that everyone thinks the Oxford vaccine will be the first in actual use maybe before the end of winter. Indeed, may take time (and more data) before Pfizer get approvals. So could be February before vaccinations even start.
Yes, sending medication, ethics approval, following people up when they are discharged from hospital would all be complicated for 20 countries. Perhaps with NIHR support and the increasing cases here they have changed the plan.
Interesting connections, brilliant sleuthing!
This would be great.
We are all frustrated by how long it is taking to get this out and save lives. For a tiny company it would be hopeless trying to meet world demand on their own. This would mean production/distribution and pricing to large populations can happen but be outsourced.
Hopefully still some profit for SNG included. I do think they would like to save the world, Stephen Holgate is a doctor, and reputed to be very committed. However, I also think RM knows the value of this and will not want to give it away.
Another old article. Looks as if providing voluntary licencing in this way with an agreement on profit sharing is being done by patent holders to preempt compulsory licences being issued by the Indian Government with no profits.
If there is truth in rumours of licence agreements with India, there may be little or no cash upfront, but looks like this is necessary to gain a share of profits for patent holders from this limited research. If this pans out, another blinder by RM.
https://www.livemint.com/Home-Page/f0R9060osU7bENFNwlnx5O/Compulsory-licences-may-spur-more-voluntary-licensing-deals.html
Ah, slightly more detail here. The licences are royalty free until WHO declares end of emergency, or a vaccine is given approval, whichever is earlier. So presumably royalties are imminent if/when a vaccine is approved.
https://www.gilead.com/purpose/advancing-global-health/covid-19/voluntary-licensing-agreements-for-remdesivir
Looks like Gilead did this - agreement with four Indian companies to produce and supply Remdesivir to 127 other countries at a price of their choosing. No mention of money, but the agreement is royalty free until the end of the pandemic. Would be very altruistic of Gilead if there was not payment involved. This was some months ago, but could be a model.
https://www.newindianexpress.com/business/2020/may/14/four-indian-firms-ink-licensing-pact-with-gilead-for-covid-19-drug-remdesivir-2143054.html
Sorry Poker I didn't mean to copy you!
This board moves so fast it is hard to keep up.
I rarely post because if I have something to say someone has already said it before I can type!
Which is all great.
But Mac, RM does not seem out of his depth at all.
The Phase III trial is already planned and funded.
It will be carried out in 20 countries by Paroxitel ? and is due to begin recruitment hopefully in November, so in the next week or two. In addition it has priority status in Uk where 20 hospital will be contributing to the total of 900 recruits targeted in the protocol. RM has suggested that recruitment will complete within 2 months and it may be faster.
They may be able to have an interim data readout so for patients recruited in less than two months with a view to an emergency use application.
It seems likely that Synairgen will need a bigger partner to help when demand vastly exceeds the 100,000 doses per month Synairgen have planned for 2021 on their own. But, RM and Synairgen are doing very very well going it alone so far. Possibly far faster than if they had 'help', and without giving away anything to BP.
No coverage from BBC or Guardian so far. Maybe they will have more depth coverage over the weekend with interviews etc.
While vaccines are great news for the world it has meant a less than sparkling week for us.
Thinking about this though. at the moment all priorities are going in to firefighting people who are dying or at death's door. It may be that only when vaccines have cleared the sheer load of cases that anyone will have space to worry about the less severe cases and get tests result to treat early/try to keep people out of hospital.
At the moment we are only able to plan for 100,000 treatments per month. This demand will be far exceeded even with a vaccine for people who didn't sero-convert (the 10% and probably increasing as the vaccine wears off) and the people who couldn't and didn't take it.
Perhaps it is only with a vaccine in action that thoughts will turn to the SNG niche.
Pmjh - There had been a lot of public questions on the vaccine to Matt Han****. Then Merryn Somerset-Webb argued that we also need to keep going with therapeutics and understanding how we live with covid in the meantime. How we now know that we can go shopping etc and are getting better at this. She then mentioned continued need for therapeutics. Firstly mentioned dexamethasone and then a study of inhaled interferon. She did not mention us by name, but clear what she was talking about. She gave a long speech and the Synairgen bit was not taken up by Matt Han**** further.
She writes in Moneyweek and is very well informed, so would know exactly about Synairgen and what she was saying I am sure.
Writing this from memory after watching it last night, so sorry this is not verbatim.